[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.232.62.209. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 19, 1941

A FOLLOW-UP REPORT ON RHEUMATIC SUBJECTS TREATED WITH SULFANILAMIDE

Author Affiliations

New York
From the Department of Medicine, Columbia University College of Physicians and Surgeons, and the Presbyterian Hospital.

JAMA. 1941;117(3):176. doi:10.1001/jama.1941.72820290004005b
Abstract

The use of sulfanilamide to prevent hemolytic streptococcus infections and recrudescences of acute rheumatism in persons known to be subject to rheumatic fever has given encouraging results. The observations by Thomas and her collaborators1 working with adults in Baltimore, and observations on children in New York2 indicated that a level of sulfanilamide in the blood of about 40 micrograms per cubic centimeter maintained throughout the school year protected against streptococcic pharyngitis and rheumatic recrudescences. One factor that it was impossible to control in the New York study was the increasing age of the group. Between 1936 and 1939 many of the children passed puberty, and, as is well recognized, rheumatic subjects tend to have fewer recrudescences in adolescence than during childhood. It was therefore possible to regard the increasing age of our patients as largely contributory to the decreased incidence of rheumatic fever.

One way of determining whether

×